Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccine immunogenicity in frail versus non-frail older adults in the Doetinchem Cohort
2020-003620-16Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- May 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of 23-valent pneumococcal polysaccharide vaccine and influenza vaccine in pneumococcal disease, influenza and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoints: Antibody levels for all PPV23 vaccine serotypes and Antibody levels for 4 influenza vaccine types. Started May 2021; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccineinfluenza vaccine
03
Conditions
pneumococcal diseaseinfluenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003620-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003620-16.